Navigation Links
ViroPharma Incorporated Reports First Quarter 2009 Financial Results
Date:4/29/2009

- Company Achieves Record First Quarter of Net Product Sales; Quarter Highlighted by Nearly $7 Million in Net Sales of Cinryze(TM) C1 Esterase Inhibitor (Human) -

EXTON, Pa., April 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the first quarter ended March 31, 2009.

  • First quarter 2009 adjusted net income of $11.5 million, and GAAP net loss of $59.2 million; the difference is primarily associated with $65 million non-cash write-off of goodwill;
  • $60 million in net product sales, including $6.7 million in net sales of Cinryze(TM) (C1 esterase Inhibitor [human]);
  • Working capital of $301 million as of the end of the first quarter of 2009, which includes cash and cash equivalents of $245 million; and
  • $45 million principal amount of its senior convertible notes repurchased for $21.2 million.

Net sales of Cinryze and Vancocin(R) were $60.2 million for the first quarter of 2009 as compared to $50.9 million for Vancocin only in the first quarter of 2008, representing 18 percent growth in net product sales.

The Company is reporting both GAAP Net income (loss) and adjusted results. Adjusted net income is GAAP Net income excluding (1) non-cash interest expense including portions related to the adoption of FSP APB 14-1 as described below; (2) amortization related to the acquisition of Lev Pharmaceuticals and Vancocin, and step up in inventory related to purchase accounting arising from our acquisition of Lev Pharmaceuticals, (3) stock compensation expenses, and (4) certain non-recurring events such as the goodwill write off arising from our book value being lower than our market capitalization at March 31, 2009, and gain on extinguishment of repurch
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
2. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. ViroPharma to Present at Three November Healthcare Conferences
5. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
6. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
7. ViroPharma to Present at Three October Healthcare Conferences
8. ViroPharma to Present at Three September Healthcare Conferences
9. ViroPharma To Acquire Lev Pharmaceuticals
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Albumin Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... The report provides a basic overview of the ... The human albumin market analysis is provided for the ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... a FM-4910 listed material, to stay competitive in ... These high-performance materials ultimately impact product quality ... President and owner. , Established in 1980 in ... strong as many fabricators have left the business. ...
(Date:9/18/2014)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an ... for cancer, announced today that Daniel P. Gold , ... NewsMakers in the Biotech Industry conference on Friday, ... Millennium Broadway Hotel & Conference Center in New ... be accessed at www.meipharma.com . A replay will be ...
(Date:9/18/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ... but separate underwritten offerings of 10,000,000 shares of its ... $2.00 per share, for expected gross proceeds of $20 ... Preferred Stock at a price to the public of ... million. Each share of Series A Convertible Preferred Stock ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... NEW YORK, Sept. 8, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0611079/Global-D-Amino-Acids-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechno This ... Acids in US$ Million. The report provides ...
... Sept. 8, 2011 Reportlinker.com announces that a ... its catalogue: Global Metabolomics ... This report analyzes the worldwide ... report provides separate comprehensive analytics for the ...
... a single set of chromosomes for the first time ... The technique should allow scientists to better establish the ... usually contain two sets of chromosomes one set ... genetic information contained in these chromosome sets helps determine ...
Cached Biology Technology:Global D-Amino Acids Industry 2Global D-Amino Acids Industry 3Global D-Amino Acids Industry 4Global D-Amino Acids Industry 5Global D-Amino Acids Industry 6Global D-Amino Acids Industry 7Global D-Amino Acids Industry 8Global D-Amino Acids Industry 9Global D-Amino Acids Industry 10Global D-Amino Acids Industry 11Global D-Amino Acids Industry 12Global D-Amino Acids Industry 13Global D-Amino Acids Industry 14Global D-Amino Acids Industry 15Global D-Amino Acids Industry 16Global Metabolomics Industry 2Global Metabolomics Industry 3Global Metabolomics Industry 4Global Metabolomics Industry 5Global Metabolomics Industry 6Global Metabolomics Industry 7Scientists create mammalian cells with single chromosome set 2
(Date:9/18/2014)... researchers from McGill University and the Quebec government ... ,microbeads, Canadian Journal of Fisheries and Aquatic ... cosmetics, household cleansers, or industrial cleansers, to which ... their small size and buoyancy, they may readily ... a global contaminant in the world,s oceans, but ...
(Date:9/18/2014)... Our genetic information is stored in DNA, tiny strands ... of our bodies. To express this genetic data, our ... the instructions into proteins that perform tasks in our ... new type of RNA molecule. Unlike all other known ... RNA. Although circRNA molecules are abundant, little has been ...
(Date:9/18/2014)... disciplines will be celebrated tonight at the third annual ... the health of premature infants and in paving the ... whose work was supported by the National Science Foundation, ... Energy Commission, will be honored at a ceremony at ... group of Members of Congress will be on hand ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 23rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... based compounds, which are 8-mer LNA oligonucleotides, successfully inhibit ... a variety of diseases, including cancer, viral infections, cardiovascular ... affinity and target specificity of tiny LNA-based compounds enabled ... of tissues without off-target effects Tiny ...
... is a health problem that affects hundreds of ... billion every year in North America. Researchers from the ... Canada say they are gaining a deeper understanding of ... treatment using antibodies from llamas. "We have found ...
... NY) Researchers at Albert Einstein College of Medicine ... enzyme family found in humans and throughout the plant and ... Their findings suggest an entirely new strategy for treating conditions ... Sharp, Ph.D. , associate professor of physiology & biophysics ...
Cached Biology News:New data published in Nature Genetics demonstrate that tiny LNA-based compounds developed by Santaris Pharma A/S inhibit entire disease-associated microRNA families 2New data published in Nature Genetics demonstrate that tiny LNA-based compounds developed by Santaris Pharma A/S inhibit entire disease-associated microRNA families 3Researchers step closer to treatment of virulent hospital infection 2Enzyme can steer cells or possibly stop them in their tracks 2
Fast, sensitive quantitation of Mouse IgM concentration....
... 200 g of lyophilized peptide derived from ... acids 380-402; GLTPSAWEASSLRSSRHSGLSHF. This peptide ... of Cayman's EP1 receptor polyclonal antibody (Catalog ... conjunction with this antibody to block protein-antibody ...
... x 25 mm; approximately 1 mm thick, ... sections, sandblasted frosted writing ... markings will not rub off or wash off ... store at room temperature ...
Complete cell culture media with cytokines...
Biology Products: